Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

Qian-Ya Fan; Xiao-Dong Zhang; Ze-Di Hu; Shi-Shi Huang; Shi-Guo Zhu; Cai-Ping Chen; Xiong Zhang; Jian-Yong Wang

doi:10.3389/fneur.2022.961758

Frontiers in Neurology (Sep 2022)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

Qian-Ya Fan,
Xiao-Dong Zhang,
Ze-Di Hu,
Shi-Shi Huang,
Shi-Guo Zhu,
Cai-Ping Chen,
Xiong Zhang,
Jian-Yong Wang

Affiliations

Qian-Ya Fan: Department of Neurology, The First People's Hospital of Jiande, Hangzhou, China
Xiao-Dong Zhang: Department of Cerebral Surgery, The First People's Hospital of Jiande, Hangzhou, China
Ze-Di Hu: Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China
Shi-Shi Huang: Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China
Shi-Guo Zhu: Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China
Cai-Ping Chen: Central Blood Bank of Jiande, Hangzhou, China
Xiong Zhang: Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China
Jian-Yong Wang: Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China

DOI: https://doi.org/10.3389/fneur.2022.961758
Journal volume & issue: Vol. 13

Abstract

Read online

IntroductionBlepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.Case presentationWe herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.ConclusionThe current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.

Published in Frontiers in Neurology

ISSN: 1664-2295 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
Website: https://www.frontiersin.org/journals/neurology/

About the journal

Abstract

Keywords